In addition, Ribavirin has a multiple dose half-life of 12 days,
and it may persist in non-plasma compartments for as long as 6 months. Therefore,
Ribavirin, including Ribavirin tablets, is contraindicated in women who are pregnant and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during therapy and for 6 months after completion of therapy in both female patients and in female partners of male patients who are taking Ribavirin therapy.